摘要
目的观察氨氯地平加替米沙坦对轻、中度高血压的疗效,探讨高血压患者血管加压素(AVP)和一氧化氮(NO)的变化与疗效的关系。方法将60例轻、中度高血压病患者(包括:正在服用降压药的高血压病患者和新发病例没有服用降压药的患者)随机分为:氨氯地平组,替米沙坦组和氨氯地平+替米沙坦组(氨+替组),每组各20例。测定各组治疗前后血压的变化。采用放免法、比色法测定各组患者治疗前后血浆AVP和NO的含量。结果①氨氯地平组、替米沙坦组及氨+替组治疗前收缩压(SBP)分别为:(146.31±3.15)mmHg、(145.92±2.71)mmHg及(146.00±2.42)mmHg;舒张压(DBP)分别为:(93.77±2.39)mmHg、(92.54±2.68)mmHg及(94.93±1.15)mmHg。在治疗6个月后,SBP分别为:(126.69±1.74)mmHg、(126.08±1.52)mmHg及(102.71±2.20)mmHg;DBP分别为:(80.76±1.13)mmHg、(81.00±0.80)mmHg和(76.11±1.36)mmHg,与治疗前比较明显降低(P<0.05)。氨+替组患者的SBP和DBP均明显低于氨氯地平组和替米沙坦组(P<0.05);氨氯地平组与替米沙坦组比较无显著差异。②治疗1月、2月末,氨+替组患者的血压达标率均明显高于氨氯地平组和替米沙坦组(P<0.05);氨氯地平组和替米沙坦组比较无显著差异。③氨氯地平组、替米沙坦组及氨+替组治疗前血浆NO的含量分别为:(12.77±0.23)μmol/L、(11.68±0.35)μmol/L及(10.09±1.04)μmol/L;治疗6个月后其含量分别为:(18.50±2.14)μmol/L、(19.07±1.96)μmol/L及(25.47±1.84)μmol/L,与治疗前比较差异显著(P<0.05)。氨+替组患者NO的含量明显高于氨氯地平组和替米沙坦组(P<0.05);氨氯地平组和替米沙坦组比较无显著差异。④氨氯地平组、替米沙坦组及氨+替组患者治疗前血浆AVP的含量分别为:(34.71±4.36)ng/L、(33.07±3.77)ng/L及(35.06±4.12)ng/L;治疗6个月后分别为:(22.35±2.71)ng/L、(24.12±3.11)ng/L及(17.98±1.79)ng/L,与治疗前比较差异显著(P<0.05)。氨+替组血浆AVP的含量低于氨氯地平组和�
AIM To observe the effect of amlodipine plus telmisartan on mild to moderate hypertension and to explore the changes of arginine vasopressin （AVP） and nitric oxide （NO） and their relationship to the therapeutic results in patients with essential hypertension. METHODS Sixty cases of mild to modcrate hypertensive patients were randomly divided into： amlodipine group, telmisartan group and amlodip- ine ＋ telmisartan group （n = 20, each）. Blood pressure was measured, and plasma AVP and NO were measured by RIA and colorimetrie method before and after treatment. RESULTS After six months＇ treatment, systolic blood pressure （SBP） and diastolic blood pressure （DBP） in the three groups decreased significantly （ P 〈 0. 05 ）. SBP and DBP in amlodipine ＋ telmisartan group were lower than those in amlodipine group and telmisartan group （ P 〈 0.05 ） , but no significant difference was observed between amlodipine group and telmisartan group. After one and two months＇ treatment, the rate of well- controlled blood pressure in amlodipine ＋ telmisartan group was higher than that in amlodipine or telmisar- tan group （P 〈 0. 05 ）, and no significant difference was observed between amlodipine group and telmis- artan group. After six months＇ treatment, the plasma NO content increased significantly in the three groups （P 〈 0. 05 ）. The plasma NO content in amlodipine ＋ telmisartan group was significantly higher than that in amlodipine group or telmisartan group （P 〈 0.05 ） , with no significant difference between the latter two groups. The plasma AVP content decreased significantly in the three groups （P 〈 0. 05 ）. The plasma AVP in amlodipine ＋ telmisartan group was significantly lower than that in amlodipine group or telm- isartan group （P 〈 0. 05）, with no significant difference between the latter two groups. CONCLUSION Though single administration of amlodipine or tehnisartan well controls blood pressure, amlodipine com- bined with telmisartan achieves be
出处
《心脏杂志》
CAS
2009年第3期362-366,共5页
Chinese Heart Journal
基金
国家十一五科技支撑计划子课题项目资助(2006BAI01A03)
